DNA Damage

Items 201-250 of 3581

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. HDAC4/5 inhibitor

    LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor.
  2. HDAC inhibitor

    4SC-202 is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity.
  3. Topoisomerase II inhibitor

    Nemorubicin is an anticancer drug with IC50 value of 0.08 uM. It is active on tumors resistant to alkylating agents, topoisomerase II inhibitors and platinum derivatives. It works primarily through topoisomerase I inhibition.
  4. SIRT2 inhibitor

    AK-1 inhibits SIRT2 selectively over SIRT1 and SIRT3.
  5. PARP-1 inhibitor

    TAK1/MAP4K2 inhibitor 1 is a potent dual inhibitor targeting transforming growth factor β-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2), exhibiting IC₅₀ values of 41.1 nM and 18.2 nM, respectively.

  6. Telomerase Activator

    Epithalon is a synthetic tetra-peptide (Ala-Glu-Asp-Gly),which regulated pineal secretion processes, presumably, via protooncogenes.
  7. HDAC inhibitor

    ST7612AA1 is a new and potent HDAC inhibitor with potential anticancer activity.
  8. APE1 Redox Inhibitor

    E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.
  9. Ethynylcytidine is a synthetic cytidine nucleoside containing a covalently bound ethynyl group with potential antineoplastic and radiosensitizing activities.
  10. SIRT 6 inhibitor

    OSS-128167, also known as SIRT6-IN-1, is a potent and selective SIRT 6 inhibitor with IC50 value of 89 μM.
  11. DNA-PK inhibitor

    Nedisertib, also known as M-3814, MSC2490484A, is an orally available inhibitor of DNA-dependent protein kinase (DNA-PK), with potential antineoplastic and chemo/radiosensitizing activities.
  12. PARP inhibitor

    Pamiparib, also known as BGB-290, is a highly potent and selective PARP inhibitor with favorable drug metabolism and pharmacokinetic properties. CAS: 1446261-44-1 (free base) 2086689-94-1 (maleate) 2086689-93-0 (hydrate)
  13. HDAC8 inhibitor

    HDAC8-IN-1, is a HDAC8 inhibitor with an IC50 of 27.2 nM in cancer cell lines.
  14. Azoxymethane is a colon carcinogen which leads to the formation of DNA adducts.
  15. NHEJ inhibitor

    SCR7 pyrazine is an inhibitor of nonhomologous end-joining (NHEJ).
  16. SIRT3 inhibitor

    3-TYP is a SIRT3 inhibitor.
  17. SIRT2 inhibitor

    Thiomyristoyl is a potent and specific SIRT2 inhibitor with an IC50 of 28 nM.
  18. Cytidine deaminase Inhibitor

    Tetrahydrouridine is a competitive, reversible inhibitor of cytidine deaminase (Ki values = 54 and 240 nM for human and E. coli enzymes, respectively).
  19. GARFT inhibitor

    Pelitrexol is a GARFT inhibitor, and is also a water soluble antifolate with anti-proliferative activity.
  20. SIRT6 allosteric activator

    MDL-800 is a first-in-class cellularly active SIRT6 allosteric activator.
  21. Sulfamonmethoxine is a competitive inhibitor of dihydropteroate synthetase, blocking the synthesis of folic acid.
  22. DNA/RNA Alkylator

    Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.
  23. Procaine hydrochloride is a local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block.
  24. Cinoxacin was an older synthetic antimicrobial related to the quinolone class of antibiotics with activity similar to oxolinic acid and nalidixic acid.
  25. Anthralin, also known as Dithranol, is a hepsin activity inhibitor used for treatment of psoriasis Inhibition of hepsin activity suppresses the invasive growth of the tumor. Anthralin exerts a direct effect on keratinocytes and leukocytes. Anthralin significantly prolonged the prophase of mitotic keratinocytes in subtoxic doses and suppressed the expression of keratin 6 mRNA in the immediately suprabasal layer of psoriatic epidermis in vivo. Anthralin also inhibits the transformation of lymphocytes and the release of reactive oxygen species from activated leukocytes, in vitro.
  26. nucleoside

    Thymidine is a nucleoside in which THYMINE is linked to DEOXYRIBOSE. Thymidine is a DNA synthesis inhibitor that can arrest cell at G1/S boundary, prior to DNA replication.

  27. Clevudine is an antiviral drug for the treatment of hepatitis B.
  28. Nimustine hydrochloride is an antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine.
  29. nucleoside analog

    Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM.
  30. topoisomerase II inhibitor

    Amsacrine hydrochloride (m-AMSA hydrochloride; acridinyl anisidide hydrochloride) is an inhibitor of topoisomerase II, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.
  31. topoisomerase IIα inhibitor

    Dexrazoxane is an intracellular iron chelator and an inhibitor of topoisomerase IIα.
  32. HDAC inhibitor

    Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC50s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9.
  33. antifolate agent

    Methotrexate (Amethopterin) disodium, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate disodium, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia).
  34. Xanthopterin hydrate, an unconjugated pteridine compound, is the main component of the yellow granule in the Oriental hornet bear wings, produces a characteristic excitation/emission maximum at 386/456 nm.
  35. PARP inhibitor

    Rucaparib Camsylate is an inhibitor of PARP with a Ki of 1.4 nM for PARP1, and also shows binding affinity to eight other PARP domains.
  36. PARP1 and PARP2 inhibitor

    Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively.
  37. Topoisomerase I inhibitor

    Belotecan, also known as CKD-602, is the semi-synthetic camptothecin analogue belotecan with potential antitumor activity.
  38. topoisomerase II inhibitor

    Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.
  39. Gemifloxacin Mesylate is a third generation antibacterial quinolone agent that is also fluorinated.
  40. PARG inhibitor

    Ethacridine lactate is a topically applied anti-infective agent. Ethacridine lactate is a poly(ADP-ribose) glycohydrolase (PARG) inhibitor.
  41. Lurbinectedin (PM01183) is a new DNA minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC50 values of 1.25 and 1.16 nM, respectively.
  42. Treosulfan (NSC 39069;Treosulphan) is an alkylating agent with activity in ovarian cancer and other solid tumor types.
  43. HDAC6 inhibitor

    SKLB-23bb is a potent and selective inhibitor for HDAC6 with an IC50 of 17 nM and shows 25-fold and 200-fold selectivity relative to HDAC1 (IC50=422 nM) and HDAC8 (IC50=3398 nM), respectively.
  44. HDAC inhibitor

    EDO-S101 is a pan HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC50 values of 9, 9 and 25 nM, respectively.
  45. DNA Topoisomerase I inhibitor

    CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types.
  46. KRS inhibitor

    LysRs-IN-2 is a lysyl-tRNA synthetase (KRS) inhibitor with IC50s of 0.015 μM and 0.13 μM for Plasmodium falciparum lysyl-tRNA synthetase (PfKRS) and Cryptosporidium parvum lysyl-tRNA synthetase (CpKRS), respectively.
  47. DNA topoisomerase I inhibitor

    MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) drug linker. MAC glucuronide phenol-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC50 values of 113 and 67 ng/mL, respectively.
  48. Topoisomerase I inhibitor

    MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 drug linker.
  49. Ku 70/80 heterodimer protein inhibitor

    STL127705 is a Ku 70/80 heterodimer protein inhibitor, inhibits Ku70/80-DNA interaction, with an IC50 of 3.5 μM.
  50. EC0488 is used to synthesize EC0531 with folate receptor (FR)-specific and anti-tumor activities.

Items 201-250 of 3581

Page
per page
Set Descending Direction